sacituzumab govitecan,Pembrolizumab,Avelumab,Zimberelimab,Domvanalimab
Gilead Sciences,Merck,Pfizer,Arcus Biosciences,Otsuka
['sacituzumab', 'urothelial', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sacitu, govi', 'blcsm']
sacituzumab govitecan-hziy led to a promising objective response rate in platinum-ineligible patients with metastatic urothelial cancer after progression on an immune checkpoint inhibitor. #blcsm #gu23 | 
Oncology news and insights from leading researchers and cancer centers.